STOCK TITAN

[8-K] Adial Pharmaceuticals, Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 11 Jul 2025, NexPoint Residential Trust (NXRT) and its operating partnership entered into a new $200 million secured revolving credit facility with JPMorgan Chase and other lenders. The facility can be upsized by a further $200 million, giving potential total capacity of $400 million.

The revolver matures 30 Jun 2028 and may be extended one year for a 0.15% fee. Borrowings accrue interest at the Company’s option of (i) daily SOFR or term SOFR + 1.50%–2.25% or (ii) a base rate + 0.50%–1.25%, with the margin set by NXRT’s leverage ratio. Unused commitments are charged a 0.20%–0.30% fee, and amounts may be prepaid at any time without penalty.

The facility is guaranteed by NXRT and secured by proceeds from equity and capital events plus equity pledges in subsidiaries that own mortgaged property. Covenants include maximum total leverage and payout ratios, minimum fixed-charge coverage, tangible net worth, debt yield and cash-reserve requirements. Default would permit lenders to terminate commitments and demand immediate repayment.

Raymond James, a lender under the agreement, also serves as sales agent for NXRT’s at-the-market equity program.

Il 11 luglio 2025, NexPoint Residential Trust (NXRT) e la sua società operativa hanno stipulato una nuova linea di credito revolving garantita da 200 milioni di dollari con JPMorgan Chase e altri finanziatori. La linea può essere incrementata di ulteriori 200 milioni di dollari, raggiungendo una capacità totale potenziale di 400 milioni di dollari.

La linea revolving scade il 30 giugno 2028 e può essere estesa di un anno con una commissione dello 0,15%. I prestiti maturano interessi a scelta della Società tra (i) SOFR giornaliero o SOFR a termine + 1,50%–2,25% oppure (ii) un tasso base + 0,50%–1,25%, con il margine stabilito in base al rapporto di leva finanziaria di NXRT. Le linee non utilizzate sono soggette a una commissione dello 0,20%–0,30%, e gli importi possono essere rimborsati anticipatamente in qualsiasi momento senza penali.

La linea è garantita da NXRT e garantita dai proventi di eventi di equity e capitali, oltre che da pegni azionari nelle controllate che possiedono immobili ipotecati. I covenant includono limiti massimi su leva finanziaria totale e rapporti di distribuzione, copertura minima delle spese fisse, patrimonio netto tangibile, rendimento del debito e requisiti di riserva di cassa. In caso di inadempienza, i finanziatori possono recedere dagli impegni e richiedere il rimborso immediato.

Raymond James, uno dei finanziatori dell’accordo, agisce anche come agente di vendita per il programma di equity at-the-market di NXRT.

El 11 de julio de 2025, NexPoint Residential Trust (NXRT) y su sociedad operativa firmaron una nueva línea de crédito revolvente garantizada de 200 millones de dólares con JPMorgan Chase y otros prestamistas. La línea puede ampliarse en otros 200 millones de dólares, alcanzando una capacidad total potencial de 400 millones de dólares.

El crédito revolvente vence el 30 de junio de 2028 y puede extenderse un año más con una comisión del 0,15%. Los préstamos devengan intereses a opción de la Compañía entre (i) SOFR diario o SOFR a plazo + 1,50%–2,25% o (ii) una tasa base + 0,50%–1,25%, con el margen determinado por la ratio de apalancamiento de NXRT. Los compromisos no utilizados tienen una comisión del 0,20%–0,30%, y los montos pueden prepagarse en cualquier momento sin penalización.

La línea está garantizada por NXRT y respaldada por ingresos de eventos de capital y acciones pignoradas en subsidiarias que poseen propiedades hipotecadas. Los convenios incluyen límites máximos de apalancamiento total y ratios de pago, cobertura mínima de cargos fijos, patrimonio neto tangible, rendimiento de la deuda y requisitos de reserva de efectivo. En caso de incumplimiento, los prestamistas pueden terminar los compromisos y exigir el reembolso inmediato.

Raymond James, un prestamista bajo el acuerdo, también actúa como agente de ventas para el programa de capital at-the-market de NXRT.

2025년 7월 11일, NexPoint Residential Trust(NXRT)와 그 운영 파트너십은 JPMorgan Chase 및 기타 대출기관과 함께 새로운 2억 달러 담보 회전 신용 시설을 체결했습니다. 이 시설은 추가 2억 달러까지 증액 가능하여 최대 4억 달러의 총 용량을 제공합니다.

회전 신용은 2028년 6월 30일 만기이며 0.15% 수수료로 1년 연장할 수 있습니다. 차입금은 회사 선택에 따라 (i) 일일 SOFR 또는 기간 SOFR + 1.50%–2.25% 또는 (ii) 기준 금리 + 0.50%–1.25%의 이자가 부과되며, 마진은 NXRT의 레버리지 비율에 의해 결정됩니다. 미사용 약정에는 0.20%–0.30% 수수료가 부과되며, 금액은 언제든지 위약금 없이 선불 상환할 수 있습니다.

이 시설은 NXRT가 보증하며, 자본 및 주식 이벤트 수익과 모기지 담보 부동산을 소유한 자회사 지분 담보로 담보됩니다. 계약 조건에는 최대 총 레버리지 및 배당 비율, 최소 고정 비용 커버리지, 유형 순자산, 부채 수익률 및 현금 준비금 요건이 포함됩니다. 채무 불이행 시 대출기관은 약정을 종료하고 즉시 상환을 요구할 수 있습니다.

본 계약의 대출기관 중 하나인 Raymond James는 NXRT의 시장형 주식 프로그램의 판매 대리인 역할도 수행합니다.

Le 11 juillet 2025, NexPoint Residential Trust (NXRT) et son partenariat opérationnel ont conclu une nouvelle ligne de crédit renouvelable garantie de 200 millions de dollars avec JPMorgan Chase et d'autres prêteurs. Cette facilité peut être augmentée de 200 millions de dollars supplémentaires, portant la capacité totale potentielle à 400 millions de dollars.

La ligne renouvelable arrive à échéance le 30 juin 2028 et peut être prolongée d'un an moyennant des frais de 0,15 %. Les emprunts portent intérêt, au choix de la société, à (i) SOFR quotidien ou SOFR à terme + 1,50 %–2,25 % ou (ii) un taux de base + 0,50 %–1,25 %, la marge étant fixée en fonction du ratio d'endettement de NXRT. Les engagements non utilisés sont facturés entre 0,20 % et 0,30 %, et les montants peuvent être remboursés par anticipation à tout moment sans pénalité.

La facilité est garantie par NXRT et sécurisée par les produits des opérations d'équité et de capital ainsi que par des nantissements d'actions dans des filiales possédant des biens hypothéqués. Les clauses restrictives incluent des limites maximales sur l'endettement total et les ratios de distribution, une couverture minimale des charges fixes, la valeur nette tangible, le rendement de la dette et les exigences de réserve de trésorerie. En cas de défaut, les prêteurs peuvent résilier les engagements et exiger un remboursement immédiat.

Raymond James, un prêteur dans le cadre de cet accord, agit également en tant qu'agent de vente pour le programme d'émission d'actions sur le marché au comptant de NXRT.

Am 11. Juli 2025 haben NexPoint Residential Trust (NXRT) und seine Betriebspartnerschaft eine neue gesicherte revolvierende Kreditfazilität über 200 Millionen US-Dollar mit JPMorgan Chase und weiteren Kreditgebern abgeschlossen. Die Fazilität kann um weitere 200 Millionen US-Dollar aufgestockt werden, was eine potenzielle Gesamtkapazität von 400 Millionen US-Dollar ergibt.

Der Revolver läuft am 30. Juni 2028 aus und kann gegen eine Gebühr von 0,15 % um ein Jahr verlängert werden. Die Kreditaufnahme verzinst sich nach Wahl des Unternehmens entweder mit (i) täglichem SOFR oder terminiertem SOFR + 1,50 %–2,25 % oder (ii) einem Basiszinssatz + 0,50 %–1,25 %, wobei die Marge anhand des Verschuldungsgrads von NXRT festgelegt wird. Nicht genutzte Kreditlinien werden mit 0,20 %–0,30 % berechnet, und Beträge können jederzeit ohne Strafgebühr vorzeitig zurückgezahlt werden.

Die Fazilität wird von NXRT garantiert und durch Erlöse aus Eigenkapital- und Kapitalmaßnahmen sowie durch Aktienverpfändungen von Tochtergesellschaften, die mit Hypotheken belastete Immobilien besitzen, besichert. Die Auflagen umfassen maximale Gesamtverschuldung und Ausschüttungsquoten, minimale Deckung der Fixkosten, materielles Nettovermögen, Schuldenertrag und Liquiditätsreserven. Ein Zahlungsausfall berechtigt die Kreditgeber, die Zusagen zu kündigen und sofortige Rückzahlung zu verlangen.

Raymond James, ein Kreditgeber im Rahmen der Vereinbarung, fungiert außerdem als Verkaufsagent für NXRTs at-the-market Eigenkapitalprogramm.

Positive
  • $200 million revolving credit facility immediately boosts liquidity and can be upsized to $400 million.
  • Maturity to June 2028 with a one-year extension provides medium-term funding certainty.
  • No prepayment penalties allow NXRT to refinance or deleverage without cost.
Negative
  • Facility is secured and covenant-heavy, potentially limiting operational and financial flexibility.
  • SOFR-based variable rates expose NXRT to future interest-rate increases.

Insights

TL;DR: New $200M revolver enhances NXRT liquidity; leverage-linked pricing modest; overall positive.

This revolver meaningfully increases NXRT’s dry powder for acquisitions, capex and working capital, and can double to $400 million if required. The 3-year tenor (plus one-year option) aligns with apartment REIT cash-flow visibility while avoiding near-term refinancing risk. Pricing of SOFR + 1.50%–2.25% is competitive for a mid-cap REIT and scales with leverage, encouraging balance-sheet discipline. Absence of prepayment penalties gives flexibility to refinance if capital-markets conditions improve. Overall, the facility strengthens NXRT’s liquidity profile and supports growth.

TL;DR: Secured, covenant-heavy facility raises leverage and lender control; neutral impact.

The revolver is secured by equity pledges and capital-event proceeds, elevating creditor claims ahead of unsecured noteholders. Stringent covenants—maximum leverage, payout limits, fixed-charge coverage and tangible net-worth thresholds—could restrict dividend policy or growth initiatives during downturns. Variable SOFR pricing leaves earnings exposed to rate volatility. While liquidity improves, balance-sheet risk modestly rises, producing a neutral net impact.

Il 11 luglio 2025, NexPoint Residential Trust (NXRT) e la sua società operativa hanno stipulato una nuova linea di credito revolving garantita da 200 milioni di dollari con JPMorgan Chase e altri finanziatori. La linea può essere incrementata di ulteriori 200 milioni di dollari, raggiungendo una capacità totale potenziale di 400 milioni di dollari.

La linea revolving scade il 30 giugno 2028 e può essere estesa di un anno con una commissione dello 0,15%. I prestiti maturano interessi a scelta della Società tra (i) SOFR giornaliero o SOFR a termine + 1,50%–2,25% oppure (ii) un tasso base + 0,50%–1,25%, con il margine stabilito in base al rapporto di leva finanziaria di NXRT. Le linee non utilizzate sono soggette a una commissione dello 0,20%–0,30%, e gli importi possono essere rimborsati anticipatamente in qualsiasi momento senza penali.

La linea è garantita da NXRT e garantita dai proventi di eventi di equity e capitali, oltre che da pegni azionari nelle controllate che possiedono immobili ipotecati. I covenant includono limiti massimi su leva finanziaria totale e rapporti di distribuzione, copertura minima delle spese fisse, patrimonio netto tangibile, rendimento del debito e requisiti di riserva di cassa. In caso di inadempienza, i finanziatori possono recedere dagli impegni e richiedere il rimborso immediato.

Raymond James, uno dei finanziatori dell’accordo, agisce anche come agente di vendita per il programma di equity at-the-market di NXRT.

El 11 de julio de 2025, NexPoint Residential Trust (NXRT) y su sociedad operativa firmaron una nueva línea de crédito revolvente garantizada de 200 millones de dólares con JPMorgan Chase y otros prestamistas. La línea puede ampliarse en otros 200 millones de dólares, alcanzando una capacidad total potencial de 400 millones de dólares.

El crédito revolvente vence el 30 de junio de 2028 y puede extenderse un año más con una comisión del 0,15%. Los préstamos devengan intereses a opción de la Compañía entre (i) SOFR diario o SOFR a plazo + 1,50%–2,25% o (ii) una tasa base + 0,50%–1,25%, con el margen determinado por la ratio de apalancamiento de NXRT. Los compromisos no utilizados tienen una comisión del 0,20%–0,30%, y los montos pueden prepagarse en cualquier momento sin penalización.

La línea está garantizada por NXRT y respaldada por ingresos de eventos de capital y acciones pignoradas en subsidiarias que poseen propiedades hipotecadas. Los convenios incluyen límites máximos de apalancamiento total y ratios de pago, cobertura mínima de cargos fijos, patrimonio neto tangible, rendimiento de la deuda y requisitos de reserva de efectivo. En caso de incumplimiento, los prestamistas pueden terminar los compromisos y exigir el reembolso inmediato.

Raymond James, un prestamista bajo el acuerdo, también actúa como agente de ventas para el programa de capital at-the-market de NXRT.

2025년 7월 11일, NexPoint Residential Trust(NXRT)와 그 운영 파트너십은 JPMorgan Chase 및 기타 대출기관과 함께 새로운 2억 달러 담보 회전 신용 시설을 체결했습니다. 이 시설은 추가 2억 달러까지 증액 가능하여 최대 4억 달러의 총 용량을 제공합니다.

회전 신용은 2028년 6월 30일 만기이며 0.15% 수수료로 1년 연장할 수 있습니다. 차입금은 회사 선택에 따라 (i) 일일 SOFR 또는 기간 SOFR + 1.50%–2.25% 또는 (ii) 기준 금리 + 0.50%–1.25%의 이자가 부과되며, 마진은 NXRT의 레버리지 비율에 의해 결정됩니다. 미사용 약정에는 0.20%–0.30% 수수료가 부과되며, 금액은 언제든지 위약금 없이 선불 상환할 수 있습니다.

이 시설은 NXRT가 보증하며, 자본 및 주식 이벤트 수익과 모기지 담보 부동산을 소유한 자회사 지분 담보로 담보됩니다. 계약 조건에는 최대 총 레버리지 및 배당 비율, 최소 고정 비용 커버리지, 유형 순자산, 부채 수익률 및 현금 준비금 요건이 포함됩니다. 채무 불이행 시 대출기관은 약정을 종료하고 즉시 상환을 요구할 수 있습니다.

본 계약의 대출기관 중 하나인 Raymond James는 NXRT의 시장형 주식 프로그램의 판매 대리인 역할도 수행합니다.

Le 11 juillet 2025, NexPoint Residential Trust (NXRT) et son partenariat opérationnel ont conclu une nouvelle ligne de crédit renouvelable garantie de 200 millions de dollars avec JPMorgan Chase et d'autres prêteurs. Cette facilité peut être augmentée de 200 millions de dollars supplémentaires, portant la capacité totale potentielle à 400 millions de dollars.

La ligne renouvelable arrive à échéance le 30 juin 2028 et peut être prolongée d'un an moyennant des frais de 0,15 %. Les emprunts portent intérêt, au choix de la société, à (i) SOFR quotidien ou SOFR à terme + 1,50 %–2,25 % ou (ii) un taux de base + 0,50 %–1,25 %, la marge étant fixée en fonction du ratio d'endettement de NXRT. Les engagements non utilisés sont facturés entre 0,20 % et 0,30 %, et les montants peuvent être remboursés par anticipation à tout moment sans pénalité.

La facilité est garantie par NXRT et sécurisée par les produits des opérations d'équité et de capital ainsi que par des nantissements d'actions dans des filiales possédant des biens hypothéqués. Les clauses restrictives incluent des limites maximales sur l'endettement total et les ratios de distribution, une couverture minimale des charges fixes, la valeur nette tangible, le rendement de la dette et les exigences de réserve de trésorerie. En cas de défaut, les prêteurs peuvent résilier les engagements et exiger un remboursement immédiat.

Raymond James, un prêteur dans le cadre de cet accord, agit également en tant qu'agent de vente pour le programme d'émission d'actions sur le marché au comptant de NXRT.

Am 11. Juli 2025 haben NexPoint Residential Trust (NXRT) und seine Betriebspartnerschaft eine neue gesicherte revolvierende Kreditfazilität über 200 Millionen US-Dollar mit JPMorgan Chase und weiteren Kreditgebern abgeschlossen. Die Fazilität kann um weitere 200 Millionen US-Dollar aufgestockt werden, was eine potenzielle Gesamtkapazität von 400 Millionen US-Dollar ergibt.

Der Revolver läuft am 30. Juni 2028 aus und kann gegen eine Gebühr von 0,15 % um ein Jahr verlängert werden. Die Kreditaufnahme verzinst sich nach Wahl des Unternehmens entweder mit (i) täglichem SOFR oder terminiertem SOFR + 1,50 %–2,25 % oder (ii) einem Basiszinssatz + 0,50 %–1,25 %, wobei die Marge anhand des Verschuldungsgrads von NXRT festgelegt wird. Nicht genutzte Kreditlinien werden mit 0,20 %–0,30 % berechnet, und Beträge können jederzeit ohne Strafgebühr vorzeitig zurückgezahlt werden.

Die Fazilität wird von NXRT garantiert und durch Erlöse aus Eigenkapital- und Kapitalmaßnahmen sowie durch Aktienverpfändungen von Tochtergesellschaften, die mit Hypotheken belastete Immobilien besitzen, besichert. Die Auflagen umfassen maximale Gesamtverschuldung und Ausschüttungsquoten, minimale Deckung der Fixkosten, materielles Nettovermögen, Schuldenertrag und Liquiditätsreserven. Ein Zahlungsausfall berechtigt die Kreditgeber, die Zusagen zu kündigen und sofortige Rückzahlung zu verlangen.

Raymond James, ein Kreditgeber im Rahmen der Vereinbarung, fungiert außerdem als Verkaufsagent für NXRTs at-the-market Eigenkapitalprogramm.

false 0001513525 0001513525 2025-07-14 2025-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): July 14, 2025

 

Adial Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-38323   82-3074668
(Commission File Number)   (IRS Employer Identification No.)

 

 

4870 Sadler Road, Ste 300

Glen Allen, VA 23060

(Address of principal executive offices and zip code)

 

(804) 487-8196

(Registrant’s telephone number including area code)

 

(Former Name and Former Address)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of each exchange on which registered
Common Stock   ADIL  

The Nasdaq Stock Market LLC

((Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported, on May 23, 2025, Adial Pharmaceuticals, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $2,126,662 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025, was below the minimum requirement of $2,500,000. The letter also stated that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) and Rule 5550(b)(3), the alternative quantitative standards for continued listing on the Nasdaq Capital Market, because it did not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal year.

 

As also previously reported, on June 18, 2025, the Company consummated a best efforts offering (the “Offering”) of (i) 5,341,200 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 5,758,800 shares of Common Stock, (iii) Series D warrants (the “Series D Warrants”) to purchase up to an aggregate of 11,100,000 shares of Common Stock and (iv) Series E warrants to purchase up to an aggregate of 8,325,000 shares of Common Stock (the “Series E Warrants” and, together with the Series D Warrants, the “Common Warrants”). Each Share or Pre-Funded Warrant was sold together with one Series D Warrant and one Series E Warrant. The combined public offering price for each Share and accompanying Common Warrants was $0.3251. The combined public offering price for each Pre-Funded Warrant and accompanying Common Warrants was $0.3241. The aggregate gross proceeds from the Offering were approximately $3.6 million, before deducting placement agent fees and other offering expenses.

 

On July 10, 2025, the Company filed a Current Report on Form 8-K (the “Form 8-K Report”) stating that as of the date of the Form 8-K Report the Company believes that it has regained compliance with the stockholders’ equity requirement as a result of the Offering.

 

On July 14, 2025, the Company received a letter from Nasdaq stating that based on the Form 8-K Report the staff has determined that the Company complies with the Listing Rule 5550(b)(1).

 

Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the Company does not evidence compliance it may be subject to delisting.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 16, 2025 ADIAL PHARMACEUTICALS, INC.
   
  By: /s/ Cary J. Claiborne
  Name: Cary J. Claiborne
  Title: President and Chief Executive Officer

 

2

 

 

FAQ

What is the size of NexPoint Residential Trust's new credit facility?

NXRT entered into a $200 million revolving credit facility that can be increased to $400 million with lender consent.

When does the NXRT revolver mature and can it be extended?

The facility matures on 30 June 2028 and includes a one-year extension option for a 0.15% fee.

What are the interest rate terms on the new revolver?

Borrowings bear interest at SOFR + 1.50%–2.25% or a base rate + 0.50%–1.25%, depending on NXRT’s leverage ratio.

Are there fees on unused commitments under the credit facility?

Yes. Unused portions are subject to a 0.20%–0.30% commitment fee based on quarterly utilization.

Does the credit agreement include prepayment penalties?

No. Amounts outstanding may be prepaid at any time without premium or penalty.

What key covenants are attached to the facility?

NXRT must meet maximum leverage and payout ratios, minimum fixed-charge coverage, tangible net worth, debt yield and cash-reserve requirements.
Adial Pharmaceuticals Inc

NASDAQ:ADIL

ADIL Rankings

ADIL Latest News

ADIL Latest SEC Filings

ADIL Stock Data

5.03M
15.24M
1.75%
9.58%
10.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHARLOTTESVILLE